Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of action that it hopes to acquire via a $1.93 billion takeover of US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback